LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "trilaciclib" as a keyword



Photo from wikipedia

Abstract 6674: Single-dose trilaciclib monotherapy potentiates antitumor immunity in the neoadjuvant setting of triple-negative breast cancer by modulating the composition and effector function of peripheral immune cells

Sign Up to like & get
recommendations! Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-6674

Abstract: Intravenous administration of trilaciclib transiently arrests cyclin-dependent kinase 4/6-dependent cells in the G1 phase of the cell cycle during chemotherapy exposure. In an open-label, phase 2 study in patients with metastatic triple-negative breast cancer (TNBC;… read more here.

Keywords: single dose; trilaciclib; trilaciclib monotherapy; dose trilaciclib ... See more keywords
Photo by introspectivedsgn from unsplash

Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.

Sign Up to like & get
recommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"

DOI: 10.18553/jmcp.2022.21379

Abstract: BACKGROUND: Chemotherapy-induced myelosuppression, which commonly manifests as neutropenia, anemia, and/or thrombocytopenia, is a frequent and severe complication of standard treatment regimens for patients with extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib is a first-in-class myeloprotective… read more here.

Keywords: trilaciclib; budget impact; cost; impact ... See more keywords

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.

Sign Up to like & get
recommendations! Published in 2022 at "Future oncology"

DOI: 10.2217/fon-2022-0773

Abstract: Triple-negative breast cancer (TNBC) is an aggressive malignancy for which cytotoxic chemotherapy remains the backbone of treatment. Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor that induces transient cell cycle arrest of hematopoietic stem and… read more here.

Keywords: trilaciclib; triple negative; breast cancer; trilaciclib prior ... See more keywords